(OAKVILLE, Ontario) May 24, 2023 ­– FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the...

(TORONTO, Ontario) April 25-26, 2023 ­– It was an honour to share the FORUS Therapeutics corporate update on April 25 at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto. We are very proud of the important commercialization milestones our team...

FORUS Therapeutics is delighted to welcome Vania Brennan as Therapeutic Area Manager, Hematology/Oncology, BC/AB.  Vania is well recognized as a therapeutic expert in the field of hematology and oncology with over 20 years experience in this space, in commercial and...